Bronchoscopy & Percutaneous Biomarker Testing
Bronchoscopy Matches percutaneous Biopsy for lung Cancer Biomarker Testing, Offers Superior Safety
Table of Contents
New Guidelines Highlight Advanced Bronchoscopic Technologies
(Denver, Colo.- July 14, 2025) – A groundbreaking clinical practice guideline from the American Association of Bronchology and Interventional Pulmonology (AABIP) and the International Association for the Study of Lung Cancer (IASLC) has established that guided-bronchoscopy sampling provides tissue adequacy for complete biomarker testing comparable too percutaneous (CT-guided) biopsy. Crucially, the guidelines emphasize that bronchoscopy, notably when utilizing contemporary navigational technologies, offers a superior safety profile with fewer complications.
The comprehensive guidelines, published in the prestigious journal of Thoracic Oncology, the official journal of the IASLC, aim to clarify best practices for obtaining tissue samples for lung cancer diagnosis and treatment planning.
Bridging the Gap: Bronchoscopy vs. Percutaneous Biopsy for Lung Cancer Diagnosis
Traditionally, linear endobronchial ultrasound (EBUS) guided sampling has been the preferred method for staging accessible mediastinal lesions in lung cancer. However,for parenchymal lung lesions,both percutaneous (CT-guided) biopsy and bronchoscopic approaches have been routinely employed. Direct comparative data on the diagnostic accuracy, safety, and adequacy of material for comprehensive biomarker testing between these methods has been limited, creating uncertainty for clinicians.
This new guideline directly addresses this knowledge gap,providing evidence-based recommendations for clinicians. It evaluates the safety and sampling adequacy of bronchoscopy-guided lung parenchymal biopsies against percutaneous biopsies, and also compares endobronchial ultrasound-guided lymph node sampling with mediastinoscopy.
Key Findings: Adequacy and Safety
the extensive review of available evidence by the multidisciplinary panel revealed compelling conclusions:
Comparable Sampling Adequacy: Across the analyzed studies, bronchoscopy-guided parenchymal biopsies consistently yielded molecular-testing specimens that were equivalent in both quality and quantity to those obtained via percutaneous biopsy. This means patients undergoing bronchoscopy can expect the same level of diagnostic material for critical biomarker testing, which guides targeted therapies and immunotherapy.
enhanced Safety Profile: A significant advantage highlighted by the guidelines is the superior safety of guided bronchoscopy. The data consistently showed fewer serious complications, such as pneumothorax (collapsed lung) and significant bleeding, when compared to percutaneous approaches. This improved safety is particularly pronounced when advanced navigational bronchoscopic technologies are employed.
Implications for Clinical Practice and Patient Care
The findings of this guideline have profound implications for the management of lung cancer patients. By confirming the equivalence of tissue adequacy for biomarker testing, the guidelines empower clinicians to favor bronchoscopy in many cases, especially when patient safety is a paramount concern. The reduced risk of complications associated with bronchoscopy can lead to shorter hospital stays, fewer post-procedure interventions, and an overall improved patient experience.
The emphasis on contemporary advanced navigational bronchoscopic technologies underscores the rapid evolution of interventional pulmonology. These technologies, which may include electromagnetic navigation, robotic bronchoscopy, and advanced imaging, enhance the precision and safety of bronchoscopic procedures, further solidifying their role as a preferred modality.
The study is available for review at: https://www.jto.org/article/S1556-0864(25)00722-1/pdf00722-1/pdf).
**
Public Release. this material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s). View in full here.*